Literature DB >> 34716858

miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.

Ying Wang1, Chenming Yan2, Junxia Qi3, Chunyan Liu1, Juan Yu1, Huabin Wang4.   

Abstract

The resistance to cisplatin, the most common platinum chemotherapy drug, may confine the efficacy of treatment in epithelial ovarian cancer patients. Aberrant expression of inhibitor of apoptosis proteins set the stage for resistance to cisplatin in EOC; besides, chemosensitivity in EOC can be chalked up to dysregulation of specific miRNAs. Herein, we investigated whether there is a potential correlation between miR-874-3p and the X-chromosome-linked inhibitor of apoptosis, a member of the IAP protein family in cisplatin-resistant EOC cells. The lower expression of miR-874-3p was found in SKOV3-DDP cells; it was also in association with cisplatin-resistance in EOC cells. XIAP was found to contribute to developing platinum resistance and is an authentic target for miR-874-3p in SKOV3-DDP cells. Consistently, restoration of miR-874-3p expression reversed cisplatin resistance in such cells by modulating XIAP and NF-κB/Survivin signaling pathway. Besides, siRNA knock down of XIAP in SKOV3-DDP cells had an anti-migratory effect like those with miR-874 overexpression. Importantly, the enforced expression of XIAP rescued SKOV3-DDP cells from the cytotoxic effects of miR-874-3p. Finally, miR-874-3p sensitized EOC cells to cisplatin-induced apoptosis, at least in part, through targeting XIAP. The cytotoxic effects of miR-874-3p can be attributed to the targeting XIAP in cisplatin-resistant EOC cells. We believe that the combination of cisplatin with miR-874-3p may make a potential strategy to reverse cisplatin resistance.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chemoresistance; Cisplatin; EOC; XIAP; miR-874-3p

Mesh:

Substances:

Year:  2021        PMID: 34716858     DOI: 10.1007/s11010-021-04271-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  36 in total

Review 1.  Transcriptional regulation of the survivin gene.

Authors:  Romain Boidot; Frédérique Végran; Sarab Lizard-Nacol
Journal:  Mol Biol Rep       Date:  2013-11-07       Impact factor: 2.316

2.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

Review 3.  Screening for ovarian cancer in the general population.

Authors:  Aleksandra Gentry-Maharaj; Usha Menon
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2011-12-17       Impact factor: 5.237

Review 4.  Chemotherapy in epithelial ovarian cancer.

Authors:  Sandro Pignata; Lucia Cannella; Davide Leopardo; Carmela Pisano; Giovanni Salvatore Bruni; Gaetano Facchini
Journal:  Cancer Lett       Date:  2011-02-24       Impact factor: 8.679

Review 5.  Targeting survivin for therapeutic discovery: past, present, and future promises.

Authors:  Robert C Peery; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  Drug Discov Today       Date:  2017-05-31       Impact factor: 7.851

Review 6.  A potential role of X-linked inhibitor of apoptosis protein in mitochondrial membrane permeabilization and its implication in cancer therapy.

Authors:  Ajay K Chaudhary; Neelu Yadav; Tariq A Bhat; Jordan O'Malley; Sandeep Kumar; Dhyan Chandra
Journal:  Drug Discov Today       Date:  2015-07-30       Impact factor: 7.851

7.  Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex.

Authors:  Vinay Arora; Herman H Cheung; Stéphanie Plenchette; O Cristina Micali; Peter Liston; Robert G Korneluk
Journal:  J Biol Chem       Date:  2007-07-05       Impact factor: 5.157

8.  Risk of epithelial ovarian cancer among women with benign ovarian tumors: a follow-up study.

Authors:  Sonia Guleria; Allan Jensen; Anita Toender; Susanne K Kjaer
Journal:  Cancer Causes Control       Date:  2019-10-31       Impact factor: 2.506

Review 9.  Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs).

Authors:  Rama Rathore; Jennifer E McCallum; Elizabeth Varghese; Ana-Maria Florea; Dietrich Büsselberg
Journal:  Apoptosis       Date:  2017-07       Impact factor: 4.677

10.  Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer.

Authors:  Yiping Zhang; Furong Huang; Qingyu Luo; Xiaowei Wu; Zhihua Liu; Hongyan Chen; Yinghui Huang
Journal:  Onco Targets Ther       Date:  2018-12-05       Impact factor: 4.147

View more
  1 in total

1.  M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma.

Authors:  Ashuai Du; Shiqin Li; Yuzheng Zhou; Cyrollah Disoma; Yujie Liao; Yongxing Zhang; Zongpeng Chen; Qinglong Yang; Pinjia Liu; Sixu Liu; Zijun Dong; Aroona Razzaq; Siyi Tao; Xuan Chen; Yuxin Liu; Lunan Xu; Qianjun Zhang; Shanni Li; Jian Peng; Zanxian Xia
Journal:  Mol Cancer       Date:  2022-05-06       Impact factor: 41.444

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.